TCRT
ALAUNOS (TCRT)
NASDAQ
$1.60-$0.11 (-6.49%)
Price as of Nov 11, 2026 7:59 PM EST
  • $5.9M
    Market Cap
  • -39.58%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 38
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

No data found

No data found

Peers

Statistics

More
Day Range
$1.65
$1.86
$1.71
1-Year Range
$0.74
$4.36
$1.71
Latest Close$1.71
Change
+$0.04 (+2.34%)
Volume189,163
Market Cap$5.9M
Shares Outstanding3.4M
P/E (TTM)-0.95
Diluted EPS (TTM)-$1.81
Enterprise Value$5.8M

Information as of 11/10/2026

Company Profile

ALAUNOS THERAPEUTICS INC
ALAUNOS THERAPEUTICS INC
https://www.alaunos.com
$5.9M
Market Cap
-$4.0M
Net Income
Sector: Healthcare
Industry: Biotechnology
501 E. Las Olas Blvd., Fort Lauderdale, FL, United States, 33301
346 355 4099

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

Key Executives

  • Holger Weis
  • Ferdinand Groenewald

Current Ownership Distribution

  • Institutions572.1M (76.70%)
  • Mutual Funds168.0M (22.53%)
  • Insiders5.7M (0.77%)
  • Other0 (0.00%)